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6STATinMED Research, Ann Arbor, MI, USAA B S T R A C TBackground: According to the Turkish Ministry of Health’s guidelines,
standard double therapy, a combination of pegylated interferon-alpha
and ribavirin, was the only treatment option for patients with
hepatitis C virus (HCV) infection until the end of 2011. Objective: The
primary objective was to compare risk-adjusted clinical and economic
outcomes between treated and untreated patients with HCV infection.
Methods: Patients with HCV infection were identiﬁed from the
Turkish National Health Insurance Database (2009–2011) using Interna-
tional Classiﬁcation of Diseases, 10th Revision, Clinical Modiﬁcation codes.
The ﬁrst prescription date was designated as the index date. Mortality
and hepatocellular carcinoma (HCC) rates and health care costs of
treated and untreated patients were compared using propensity score
matching. Baseline demographic and clinical factors were controlled
in the models. Subgroup analysis was conducted for patient groups
with and without a cirrhosis diagnosis. Results: Out of 12,990 patients
included in the study, 1,583 were treated for HCV infection. Out of
2,467 patients who had a cirrhosis diagnosis, 231 were treated,ee front matter Copyright & 2015, International S
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, NY.whereas out of 10,523 patients without cirrhosis, 1,352 patients were
treated. Treated patients were younger, less likely to be diagnosed
with comorbid conditions, and less likely to reside in Central or
Eastern Anatolia. After adjusting for baseline demographic and
clinical factors, mortality (2.27% vs. 5.31%; P o 0.001) and HCC rates
(0.69% vs. 1.96%; P o 0.001) were found to be lower for treated
patients. Differences were more signiﬁcant among patients diagnosed
with cirrhosis. Treated patients incurred higher risk-adjusted annual
costs (€6172 vs. €1680; P o 0.001), mainly because of pharmaceutical
costs (€4918 vs. €583; P o 0.001). Conclusions: HCV infection treat-
ment, although costly, signiﬁcantly reduces mortality and HCC rates
in Turkey.
Keywords: complications, health care costs, health care utilization,
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Hepatitis C virus (HCV) is a major global public health concern. It
is estimated that 2% to 3% of the population in the world (130–170
million people) is infected with HCV infection [1]. With higher
incidence in the southern and eastern regions, there are
approximately 9 million patients with HCV infection in Europe
[2–6].
Most acute HCV infections (60%–70%) are asymptomatic;
therefore, many chronically infected patients do not know that
they have been infected with HCV [7,8]. Individuals at an
increased risk of HCV infection are injectable drug users, chronic
hemodialysis patients, and recipients of blood or blood product
transfusions before the 1990 s (up to 70%, 15%, and 10%, respec-
tively) [9–11]. Other risk factors for HCV transmission include
unprotected sex, perinatal transmission, needle stick injury, and
receipt of immunoglobulin [12].In Turkey, HCV has a 2.2% seroprevalence [8] where almost
90% of the patients are infected with HCV genotype 1b, except in
the city of Kayseri and its vicinity, where HCV genotype 4
accounts for 35% of the patients admitted to hospitals [13,14].
In 2005, Turkey had the lowest HCV infection treatment rates
among European countries [15].
Treatment possibilities have improved dramatically over the
past decade. As much as 51% of patients infected with HCV
genotypes 1 or 4 and 90% of patients infected with HCV geno-
types 2 or 3 can be cured after 24 to 48 weeks of antiviral
treatment [16]. The main goal of treatment in chronic hepatitis
C is the prevention of cirrhosis and hepatocellular carcinoma
(HCC) by suppressing the virus to undetectable levels, and the
efﬁcacy of antiviral HCV treatment is measured through sus-
tained virologic response (SVR).
The standard treatment for chronic HCV infection includes
the double therapy combination of pegylated interferon-alphaociety for Pharmacoeconomics and Outcomes Research (ISPOR).
conﬂicts of interest with regard to the content of this article.
nter for Innovation and Outcomes Research, 145 Hudson Street,
Fig. 1 – Patient selection criteria. HCV, hepatitis C virus; Peg-IFN-α, pegylated interferon-alpha.
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Two treatment strategies are being evaluated, which include
adding one or two direct-acting antiviral agents to the standard
double therapy and an oral direct-acting antiviral agent combi-
nation designed to inhibit different steps of the HCV life cycle
[15,18,19]. According to the Turkish Ministry of Health’s guide-
lines, standard double therapy is the only option to treat naive
patients with HCV infection [20]. Although combination therapy
of Peg-IFN-α and ribavirin signiﬁcantly increases SVR and the
probability of reaching SVR by 50%, the degree of response
depends on various factors.
The clinical and economic burden of HCV is signiﬁcant.
Approximately 80% of the individuals exposed to HCV develop
chronic infections, and 3% to 11% of those with chronic HCV
infections will develop cirrhosis within 20 to 30 years [21,22] with
the associated risk of liver failure and HCC [23,24]. HCV infection
causes approximately 365,000 deaths annually as a result of
complications [15]. In 2002, the number of estimated HCV-
related deaths in Europe was 86,000 [3]. HCV doubles the risk of
depression, increases the risk of HCC 25-fold, the risk of needing
a liver transplant more than 60-fold, and the risk of cirrhosis 80-
fold [25]. Existing literature indicates that chronic HCV infection
lowers work productivity, increases health care utilization, and is
associated with an elevated risk of liver-related morbidity and
mortality [15].
There is limited research on the total economic burden of HCV
on the Turkish health care system. To generate real-world
evidence on the HCV-related economic burden and its resultingcomplications in Turkey, this study aimed to compare health care
outcomes between patients with HCV infection who were pre-
scribed Peg-IFN-α with or without ribavirin and those who were
not prescribed these medications.Methods
Law 5502, by the Turkish Grand National Assembly, uniﬁed three
existing social security and health insurance systems (e.g., Sosyal
Sigortalar Kurumu (SSK), Bag-kur, and Emekli Sandigi) into a
single system under the Social Security Institute (SSI) in 2006.
Enrollment in the current existing Universal Health Insurance
Fund within the SSI is mandatory, and contribution rates are
determined by patients’ ability to pay. All beneﬁciaries under the
system are entitled to the same beneﬁts package.
Payment by a health insurance fund is based on both a fee-
for-service system and a bundled payment system, depending on
disease category and services related to the particular disease.
For example, laboratory services can be paid separately through
the bundled payment system. Payment procedures are outlined
by health budget law as access to HCV medications determined
by the Ministry of Health protocol. Payment is determined by the
health budget laws of the SSI.
Recognizing the importance of health information technology
and health technology assessment, Turkey has invested in a
nationwide integrated system to collect health care utilization
outcomes electronically during the last few years. A claims and
Table 1 – Baseline descriptive characteristics for patients with HCV with/without peginterferon and ribavirin
treatment.
Characteristic Untreated HCV cohort Treated HCV cohort P value
(N ¼ 11,407 ) (N ¼ 1,583)
N/Mean %/SD N/Mean %/SD
Age (y) 53.30 15.79 51.52 12.21 o0.0001*
0–17 157 1.38% 5 0.32% 0.0004*
18–29 954 8.36% 115 7.26% 0.1361
30–39 1,123 9.84% 156 9.85% 0.9901
40–49 1,709 14.98% 284 17.94% 0.0022*
50–59 2,969 26.03% 582 36.77% o0.0001
60þ 4,495 39.41% 441 27.86% o0.0001
Sex
Female 6,523 57.18% 868 54.83% 0.0767
Geographic location (Turkey)
Aegean 1,187 10.41% 173 10.93% 0.5244
Black Sea 2,776 24.34% 390 24.64% 0.7939
Central Anatolia 2,785 24.41% 339 21.42% 0.0089
Eastern Anatolia 917 8.04% 102 6.44% 0.0269
Marmara 1,831 16.05% 291 18.38% 0.0187
Mediterranean 1,279 11.21% 174 10.99% 0.7941
Southeastern Anatolia 632 5.54% 114 7.20% 0.0078
Comorbidities
Cirrhosis 1,359 11.91% 105 6.63% o0.0001
Biliary disease 564 4.94% 85 5.37% 0.4668
Hepatitis B 1,814 15.90% 275 17.37% 0.1358
HIV 27 0.24% 5 0.32% 0.5516
Chronic artery disease 1,634 14.32% 185 11.69% 0.0046
Congestive heart failure 395 3.46% 27 1.71% 0.0002
Dialysis 141 1.24% 33 2.08% 0.0059
Respiratory diseases 1,912 16.76% 228 14.40% 0.0178
Liver cancer 234 2.05% 17 1.07% 0.0081
Other cancer 701 6.15% 77 4.86% 0.0441
Hypertension 4,273 37.46% 555 35.06% 0.0641
Diabetes 2,309 20.24% 270 17.06% 0.0029
Psychological disorders 1,909 16.74% 304 19.20% 0.0144
Liver transplant 65 0.57% 5 0.32% 0.1959
Hepatic encephalopathy 7 0.06% 0 0.00% 0.3242
Anemia 1,950 17.09% 256 16.17% 0.3594
Rash 11 0.10% 0 0.00% 0.2164
Pruritus 343 3.01% 49 3.10% 0.8471
Nausea 494 4.33% 81 5.12% 0.1541
Diarrhea 863 7.57% 108 6.82% 0.2922
HCV, hepatitis C virus; HIV, human immunodeﬁciency virus.
* Signiﬁcant at 10%.
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Health Budget Law (SUT). All public and private facilities under
contract with the SSI must submit claims through this system,
which covers 80% of the population in Turkey, comprising
pharmacy, inpatient, outpatient, and laboratory claims from
17,800 pharmacies, 5600 general practitioners, 4500 medical
centers, 1200 government hospitals, and 338 private hospitals.
The remaining 20% of the population not included in the data
consists of those whose contribution rates were paid by the
government due to their income levels. In addition, members of
the Turkish Grand National Assembly and the Supreme Court, as
well as foreign insurance policy holders and some military
personnel, were excluded from the Universal Health Insurance
Fund in the SSI; therefore, their data are not in the system.
The data have been used in several outcomes research studies
[26–30].The study period was from January 1, 2009, through December
31, 2011. Using appropriate diagnosis codes from the International
Classiﬁcation of Diseases, 10th Revision, Clinical Modiﬁcation, all
patients with an HCV infection diagnosis were identiﬁed for the
identiﬁcation period (January 1, 2010, to December 31, 2010). Peg-
IFN-α therapy use was identiﬁed after HCV infection diagnosis.
The ﬁrst prescription date was designated as the index date.
Patients with Peg-IFN-α therapy before HCV infection diagnosis
and those who were pregnant during the study period were
excluded from the study sample. All patients had continuous
health insurance enrollment during the 1-year preindex (base-
line) and the 1-year postindex (follow-up) periods.
Our main cohort included patients with HCV who were
categorized into two groups: treated and untreated. Subgroup
analysis was also conducted for patients with and without a
cirrhosis diagnosis. Demographic factors including age, sex, and
Table 2 – Risk-adjusted outcomes for patients with HCV with/without peginterferon and ribavirin treatment.
Risk-adjusted Outcome Untreated HCV cohort Treated HCV cohort P value
(N ¼ 1583) (N ¼ 1583)
N/Mean %/SD N/Mean %/SD
Adherence and clinical events
Mortality 84 5.31% 36 2.27% o0.0001
Hepatocellular carcinoma 31 1.96% 11 0.69% 0.0019
HCV health care costs (€)
All-cause inpatient costs 467.38 2893.01 283.00 1863.76 0.0331
All-cause outpatient costs 564.58 1497.86 958.77 1939.26 o0.0001
All-cause pharmacy costs 583.91 2230.48 4918.58 2827.44 o0.0001
All-cause co-pays 14.33 14.51 12.17 14.70 o0.0001
All-cause overall costs 1630.20 4396.51 6172.52 4000.77 o0.0001
HCV, hepatitis C virus.
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teristics, we identiﬁed individual comorbidities, such as biliary
disease, hepatitis B, human immunodeﬁciency virus, chronic
artery disease, congestive heart failure, dialysis, respiratory dis-
eases, liver cancer, other cancers, hypertension, diabetes, psy-
chological disorders, liver transplant, hepatic encephalopathy,
anemia, rash, pruritus, nausea, and diarrhea. Means and SDs
were calculated for all continuous measures, and frequencies and
percentages were computed for categorical variables. For the
follow-up period, mortality and HCC diagnosis were identiﬁed
as clinical outcomes. In addition to overall costs, inpatient,
outpatient, and pharmacy costs were calculated from reimburse-
ment amounts as economic outcomes.
To compare these clinical and economic outcomes, risk
adjustment is necessary. When evaluating treatment groups,
selection bias may occur, as treatment and control groups differ
in terms of age, sex, region, and comorbidities. We applied
propensity score matching (PSM) to eliminate differences
between the groups. PSM uses the prediction probability of group
membership and isolates the bias resulting from observed differ-
ences. A patient’s propensity score is the probability of being
treated on the basis of the condition of the patient’s covariate
values, such as demographic and clinical factors. Two patients,
one treated and the other untreated, with the same or similar
propensity score can be considered similar for all observed
factors controlled in the predicted probability. The only differ-
ence is that one patient is treated and the other is untreated.
Following the guidelines to choose the most appropriate
matching technique for this study data, radius, kernel, mahala-
nobis, and one-to-one matching were compared, and ultimately,
one-to-one matching was applied [31]. Patient age, sex, region,
and baseline individual comorbidities were used as covariates in
the PSM model. The analysis was conducted using SAS version
9.3 (SAS Institute, Inc., Cary, NC) and STATA version 11 software
(Stata-Corp LP, College Station, TX).Results
A total of 12,990 patients were included in the study, 2,467 of
whom were diagnosed with cirrhosis and satisﬁed all inclusion
and exclusion criteria. In the patient population, 12.2% (N ¼ 1583)
of the treated patients and 9.4% (N ¼ 231) of the patients with
cirrhosis in study I and study II, respectively, and 12.8% (N ¼ 1352)
of the patients without cirrhosis in study II underwent standard
double therapy during the study period (Fig. 1).Treated versus Untreated Patients with HCV Infection
Patients treated for HCV infection were younger (age 51.52 vs.
53.30 years; P o 0.01) and less likely to reside in Central (21.42%
vs. 24.41%; Po 0.01) or Eastern Anatolia (6.44% vs. 8.04%; Po 0.03)
but more likely to reside in Marmara (18.38% vs. 16.05%; Po 0.02)
or Southeastern Anatolia (7.20% vs. 5.54%; P o 0.01). Female
patients were less likely to be treated for HCV infection (54.83%
vs. 57.18%; Po 0.08), but the difference was marginally signiﬁcant
(Table 1).
Comorbidity rates for cirrhosis (11.91% vs. 6.63%), chronic
artery disease (14.43% vs. 11.69%), congestive heart failure
(3.46% vs. 1.71%), respiratory diseases (16.76% vs. 14.40%), liver
cancer (2.05% vs. 1.07%), and diabetes (20.24% vs. 17.06%) were
signiﬁcantly higher among untreated patients during the baseline
period (P o 0.01 for all; Table 1). More untreated patients were
diagnosed with hypertension (37.46% vs. 35.06%; P o 0.07),
though the difference was marginally signiﬁcant. There were no
signiﬁcant differences between the groups for the following
comorbid conditions: biliary disease, hepatitis B, human immu-
nodeﬁciency virus, liver transplant, hepatic encephalopathy,
anemia, rash, pruritus, nausea, and diarrhea. More dialysis
patients were treated for HCV infection (2.08% vs. 1.24%; P o
0.001). To eradicate HCV infection before renal transplantation,
patients undergoing hemodialysis may have been more likely to
be treated for HCV (Table 1).
The primary objective was to compare the clinical and
economic outcomes between treated and untreated patients with
HCV. Because a descriptive comparison of outcomes was con-
founded by differences in age, region, sex, and comorbid con-
ditions, as outlined previously, PSM was used.
Table 2 presents the results after PSM. A total of 1583
patients in the untreated cohort were matched with compa-
rable patients in the treated cohort on the basis of demo-
graphic and clinical factors. Annual health care costs,
mortality, and the likelihood of HCC were calculated and
compared. This risk-adjusted comparison isolated patient
differences in terms of demographic and clinical character-
istics, as outlined in Table 1.
Risk-adjusted mortality rates (2.27% vs. 5.31%; P o 0.001) and
HCC rates (0.69% vs. 1.96%; Po 0.001) were signiﬁcantly lower for
treated patients with HCV infection. Total risk-adjusted annual
costs were signiﬁcantly higher for treated patients (€6172 vs.
€1680; Po 0.001), mainly due to higher pharmacy (€4918 vs. €583;
P o 0.001) and outpatient (€958 vs. €564; P o 0.001) costs.
Inpatient costs for treated patients were lower than for untreated
patients (€283 vs. €467; P o 0.001).
Table 3 – Baseline descriptive characteristics for patients with/without cirrhosis with/without peginterferon
and ribavirin treatment.
Characteristic Patients with cirrhosis Patients without cirrhosis
Untreated cohort Treated cohort P value Untreated cohort Treated cohort P value
(N ¼ 2236) (N ¼ 231) (N ¼ 9171) (N ¼ 1352)
N/
Mean
%/SD N/
Mean
%/SD N/
Mean
%/SD N/
Mean
%/SD
Age (y) 62.12 11.29 56.17 9.67 o0.0001 51.15 15.98 50.72 12.43 0.2519
0–17 7 0.31% 0 0.00% 0.3944 150 1.64% 5 0.37% 0.0003
18–29 20 0.89% 8 3.46% 0.0005 934 10.18% 107 7.91% 0.0091
30–39 55 2.46% 6 2.60% 0.8979 1,068 11.65% 150 11.09% 0.5546
40–49 165 7.38% 29 12.55% 0.0054 1,544 16.84% 255 18.86% 0.0648
50–59 576 25.76% 98 42.42% o0.0001 2,393 26.09% 484 35.80% o0.0001
60þ 1,413 63.19% 90 38.96% o0.0001 3,082 33.61% 351 25.96% o0.0001
Sex
Female 1,248 55.81% 131 56.71% 0.7940 5,275 57.52% 737 54.51% 0.0370
Geographic location (Turkey)
Aegean 241 10.78% 38 16.45% 0.0096 946 10.32% 135 9.99% 0.7091
Black Sea 600 26.83% 65 28.14% 0.6705 2,176 23.73% 325 24.04% 0.8017
Central Anatolia 419 18.74% 40 17.32% 0.5968 2,366 25.80% 299 22.12% 0.0036
Eastern Anatolia 139 6.22% 9 3.90% 0.1574 778 8.48% 93 6.88% 0.0456
Marmara 354 15.83% 47 20.35% 0.0766 1,477 16.11% 244 18.05% 0.0715
Mediterranean 349 15.61% 21 9.09% 0.0083 930 10.14% 153 11.32% 0.1840
Southeastern
Anatolia
134 5.99% 11 4.76% 0.4489 498 5.43% 103 7.62% 0.0012
Comorbidities
Biliary disease 193 8.63% 19 8.23% 0.8338 371 4.05% 66 4.88% 0.1502
Hepatitis B virus 476 21.29% 42 18.18% 0.2698 1,338 14.59% 233 17.23% 0.0109
HIV 1 0.04% 0 0.00% 0.7478 26 0.28% 5 0.37% 0.5846
Chronic artery
disease
388 17.35% 38 16.45% 0.7298 1,246 13.59% 147 10.87% 0.0060
Congestive heart
failure
167 7.47% 5 2.16% 0.0026 228 2.49% 22 1.63% 0.0529
Dialysis 22 0.98% 4 1.73% 0.2894 119 1.30% 29 2.14% 0.0135
Respiratory
diseases
460 20.57% 45 19.48% 0.6954 1,452 15.83% 183 13.54% 0.0295
Liver cancer 185 8.27% 8 3.46% 0.0095 49 0.53% 9 0.67% 0.5424
Other cancer 179 8.01% 10 4.33% 0.0455 522 5.69% 67 4.96% 0.2716
Hypertension 1,150 51.43% 116 50.22% 0.7251 3,123 34.05% 439 32.47% 0.2510
Diabetes 718 32.11% 60 25.97% 0.0560 1,591 17.35% 210 15.53% 0.0980
Psychological
disorders
356 15.92% 48 20.78% 0.0575 1,553 16.93% 256 18.93% 0.0687
Liver transplant 53 2.37% 4 1.73% 0.5385 12 0.13% 1 0.07% 0.5783
Hepatic enceph-
alopathy
7 0.31% 0 0.00% 0.3944 0 0.00% 0 0.00%
Anemia 567 25.36% 51 22.08% 0.2734 1,383 15.08% 205 15.16% 0.9369
Rash 3 0.13% 0 0.00% 0.5775 8 0.09% 0 0.00% 0.2773
Pruritus 110 4.92% 14 6.06% 0.4498 233 2.54% 35 2.59% 0.9165
Nausea 151 6.75% 17 7.36% 0.7277 343 3.74% 64 4.73% 0.0769
Diarrhea 225 10.06% 17 7.36% 0.1885 638 6.96% 91 6.73% 0.7600
HIV, human immunodeﬁciency virus.
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As a subgroup analysis, we examined patients with and without
cirrhosis separately. Treated patients in the cirrhosis cohort
were younger (56.17 vs. 62.12 years; Po 0.001) and more likely to
reside in the Aegean region (16.45% vs. 10.78%; P o 0.001) but
less likely to reside in the Mediterranean region (9.09% vs.
15.61%; P o 0.001). Similar to the overall population, patients
with cirrhosis with prior congestive heart failure (2.16% vs.
7.47%; P o 0.001), liver cancer (3.46% vs. 8.27%), and othercancers (4.33% vs. 8.01%) were less likely to be treated for HCV
infection (Table 3).
There were no age differences between treated and
untreated patients without cirrhosis (P ¼ 0.2519). Female
patients, however, were less likely to be included in the treated
cohort (54.51% vs. 57.52%; P o 0.001). Treated patients without
cirrhosis were less likely to reside in Central Anatolia (22.12%
vs. 25.80%; P o 0.01) or Eastern Anatolia (7.62% vs. 5.43%; P o
0.01) but more likely to reside in Marmara (18.05% vs. 16.11%;
Table 4 – Risk-adjusted outcomes for patients with/without cirrhosis with/without peginterferon and ribavirin
treatment.
Risk-adjusted
outcome
Patients with cirrhosis Patients without cirrhosis
Untreated cohort Treated cohort P value Untreated cohort Treated cohort P value
(N ¼ 231) (N ¼ 231) (N ¼ 1352) (N ¼ 1352)
N/
Mean
%/SD N/
Mean
%/SD N/
Mean
%/SD N/
Mean
%/SD
Adherence and clinical events
Mortality 53 22.94% 12 5.19% o0.0001 29 2.14% 24 1.78% 0.4879
Hepatocellular
carcinoma
24 10.39% 9 3.90% 0.0067 6 0.44% 2 0.15% 0.1567
Health care costs (€)
All-cause
inpatient
costs
1066.84 3828.93 898.98 4554.41 0.6683 192.78 1246.81 177.76 678.42 0.6972
All-cause
outpatient
costs
645.07 1469.57 883.11 1638.74 0.1009 547.63 1457.71 971.70 1986.31 o0.0001
All-cause
pharmacy
costs
756.22 1092.55 4482.96 2513.66 o0.0001 716.74 4286.99 4993.01 2871.87 o0.0001
All-cause co-
pays
16.56 13.31 14.41 19.27 0.1632 13.74 14.39 11.78 13.75 0.0003
All-cause
overall costs
2484.69 4663.04 6279.47 5703.06 o0.0001 1470.89 4971.55 6154.24 3633.66 o0.0001
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Table 3).
Baseline comorbidity rates for chronic artery disease (10.87%
vs. 13.59%), congestive heart failure (1.63% vs. 2.49%), and respi-
ratory diseases (13.54% vs. 15.83%) were signiﬁcantly lower
among treated patients without cirrhosis (Table 3). There were
more dialysis (2.14% vs. 1.30%; Po 0.001) and hepatitis B patients
(17.23% vs. 14.59%; P o 0.001) in the treated group (Table 3).
Although there were no signiﬁcant differences in risk-
adjusted mortality and HCC rates for treated and untreated
patients without a cirrhosis diagnosis (P ¼ 0.4879 and P ¼
0.1567, respectively), mortality rates decreased more than four-
fold. HCC rates decreased more than twofold for patients treated
for HCV infection in the cirrhosis cohort (5.19% vs. 22.94% and
3.90% vs. 10.39%, P o 0.001, respectively; Table 4).
Risk-adjusted total health care costs were signiﬁcantly higher
for treated patients in the populations with and without cirrhosis
(€6279 vs. €2484 and €6154 vs. €1470; P o 0.001). The difference
was mainly due to higher pharmaceutical costs in both cohorts
(€4482 vs. €756 and €4993 vs. €716; P o 0.001). There were no
signiﬁcant differences in inpatient and outpatient costs between
treated and untreated patients who were diagnosed with cirrho-
sis. The difference in outpatient costs between treated and
untreated patients without cirrhosis, however, was signiﬁcant.Discussion
Although the economic burden and complications of HCV infec-
tion have been increasingly recognized, relatively little informa-
tion is available regarding health care costs, mortality, and
complications among patients with HCV in Turkey. Nationally
representative claims data from Turkey were used for the ﬁrst
time for this outcomes assessment of patients with HCV infec-
tion. Annual direct medical costs for treated (Peg-IFN-α with or
without ribavirin) and untreated patients with HCV infection aswell as mortality and HCC rates were estimated. Treated and
untreated patients were further stratiﬁed according to cirrhosis
diagnosis.
HCV-induced liver diseases and complications were associ-
ated with signiﬁcant morbidity and mortality due to the extended
period of HCV infection. We showed that after controlling for
baseline demographic and clinical factors, treatment signiﬁcantly
reduces mortality and HCC rates among patients with cirrhosis in
Turkey but has no effect on these rates among those without the
disease. This is important to note because some expect that
cirrhosis and HCC rates will increase by approximately 80% by
the year 2020 [32].
HCV-related costs are associated with not only HCV infection
complications resulting from the advanced disease stages but
also HCV antiviral medications that are extremely expensive [33].
Current data reveal that main cost drivers in the overall costs
were inpatient and pharmacy expenditures. The share of out-
patient costs was relatively small. Vietri et al. [34] recently found
that overall direct costs of patients with HCV infection (sum of
physician visit, emergency department visit, and hospitalization
costs) were €934 on average, among ﬁve European countries
(France, Germany, United Kingdom, Italy, and Spain). Menzin
et al. [35] estimated inpatient costs at $2649 in patients with
cirrhosis, whereas costs were $337 among patients without
cirrhosis ($1 ¼ €0.75). Our results were similar (€1518 vs. €286; P
o 0.001; data not shown).
Standard antiviral therapy consisting of Peg-IFN-α and riba-
virin can be expensive. Helsper et al. [16] estimated that the cost
of adverse effects, excluding antiviral treatment costs, were as
high as €15,104. It has been shown that adding a hepatitis C
protease inhibitor (such as telaprevir and boceprevir) to standard
double therapy has greatly improved SVR rates (up to 80%–90%)
in patients infected with HCV genotype 1, but the therapy
remains costly [5,36]. Similarly, using a Markov model, Cure
et al. [37] reported higher health care costs but improved SVR
rates. Because protease inhibitors were not prescribed for HCV
V A L U E I N H E A L T H R E G I O N A L I S S U E S 7 C ( 2 0 1 5 ) 4 2 – 4 848infection treatment in Turkey during our study period, we were
unable to assess any impact of triple therapy on HCV infection
costs in Turkey.
There were also study limitations typical for any retrospective
claims database study, and any results should be interpreted
with these caveats in mind [38]. First, the analysis was based on
administrative claims data. Although claims data are extremely
valuable to analyze treatment effect, they are collected for
administrative purposes rather than research. Presence of diag-
nosis codes on medical claims may not necessarily prove the
presence of the disease because diagnoses may be incorrectly
coded or included as rule-out criteria rather than actual disease.
Occurrence of a prescription drug ﬁll does not guarantee actual
consumption of the drug by the patient. For example, the efﬁcacy
of HCV therapy is highly dependent on treatment compliance;
therefore, this study implicitly assumed that the compliance rate
did not vary across patients, other than the factors controlled in
the regression models. Also, claims data do not contain measures
of disease activity, health status, patient lifestyle, or genotype.
Although we used individual comorbidities to proxy for health
status, further studies linking claims data outcomes to hospital
charts are warranted to determine the relationship among dis-
ease activity scores, genotyping, and outcomes.Conclusions
Although imperfect, claims analysis plays an important role in
health care services research. Claims are a source of information
regarding real-world practices across different regions and practi-
ces and have variations that may be difﬁcult to assess using trial,
survey, expert opinion, and other data sources. Treated patients
incurred signiﬁcantly higher costs, mainly due to pharmaceutical
expenditures. The literature reveals that standard and triple
therapies are cost-effective because of their probability of halting
the progression of underlying liver disease. This study showed
that there was a signiﬁcant reduction in mortality and HCC rates
due to treatment among patients with cirrhosis in Turkey.Acknowledgment
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